Ameritas Investment Partners Inc. Makes New $3.18 Million Investment in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Ameritas Investment Partners Inc. acquired a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 20,105 shares of the biotechnology company’s stock, valued at approximately $3,177,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of SRPT. Riggs Asset Managment Co. Inc. raised its holdings in shares of Sarepta Therapeutics by 33.3% in the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 75 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Sarepta Therapeutics by 37.0% in the first quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 87 shares during the last quarter. Cambridge Investment Research Advisors Inc. lifted its holdings in shares of Sarepta Therapeutics by 1.9% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 6,331 shares of the biotechnology company’s stock valued at $1,000,000 after purchasing an additional 120 shares in the last quarter. WCM Investment Management LLC boosted its position in shares of Sarepta Therapeutics by 2.3% during the first quarter. WCM Investment Management LLC now owns 6,279 shares of the biotechnology company’s stock valued at $813,000 after buying an additional 142 shares during the last quarter. Finally, Innealta Capital LLC bought a new stake in Sarepta Therapeutics during the second quarter worth $31,000. Institutional investors own 86.68% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Robert W. Baird raised their price objective on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, June 21st. Bank of America raised their price target on shares of Sarepta Therapeutics from $166.00 to $213.00 and gave the company a “buy” rating in a research report on Friday, June 21st. Barclays reduced their price objective on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. UBS Group lifted their target price on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 target price on shares of Sarepta Therapeutics in a report on Thursday. Three investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $187.39.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, EVP Ryan Edward Brown sold 38,957 shares of the firm’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total value of $6,295,840.77. Following the completion of the transaction, the executive vice president now owns 17,129 shares in the company, valued at approximately $2,768,217.69. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, EVP Ryan Edward Brown sold 38,957 shares of the stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $161.61, for a total value of $6,295,840.77. Following the sale, the executive vice president now directly owns 17,129 shares of the company’s stock, valued at $2,768,217.69. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Michael Andrew Chambers acquired 37,038 shares of the business’s stock in a transaction dated Friday, August 16th. The stock was purchased at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the transaction, the director now directly owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. The disclosure for this purchase can be found here. In the last three months, insiders have sold 52,801 shares of company stock worth $8,399,586. 7.70% of the stock is owned by company insiders.

Sarepta Therapeutics Price Performance

SRPT opened at $127.21 on Friday. The firm has a 50-day moving average price of $137.26 and a 200-day moving average price of $132.66. Sarepta Therapeutics, Inc. has a twelve month low of $55.25 and a twelve month high of $173.25. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05. The company has a market capitalization of $12.02 billion, a price-to-earnings ratio of 1,156.45 and a beta of 0.81.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.06. The business had revenue of $362.90 million during the quarter, compared to analyst estimates of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. Sarepta Therapeutics’s revenue was up 38.9% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.27) EPS. Equities analysts expect that Sarepta Therapeutics, Inc. will post 1.47 EPS for the current year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.